Literature DB >> 34248112

Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas.

Cyndy Liu1, Tae Nakano-Tateno1, Motoyasu Satou1,2, Constance Chik1, Toru Tateno1.   

Abstract

Pituitary adenomas are benign tumours that can cause an individual various clinical manifestations including tumour mass effects and/or the diverse effects of abnormal pituitary hormone secretion. Given the morbidity and limited treatment options for pituitary adenomas, there is a need for better biomarkers and treatment options. One molecule that is of specific interest is the signal transducer and activator of transcription 3 (STAT3), a transcription factor that plays a critical role in mediating cytokine-induced changes in gene expression. In addition, STAT3 controls cell proliferation by regulating mitochondrial activity. Not only does activation of STAT3 play a crucial role in tumorigenesis, including pituitary tumorigenesis, but a number of studies also demonstrate pharmacological STAT3 inhibition as a promising treatment approach for many types of tumours, including pituitary tumours. This review will focus on the role of STAT3 in different pituitary adenomas, in particular, growth hormone-producing adenomas and null cell adenomas. Furthermore, how STAT3 is involved in the cell proliferation and hormone regulation in pituitary adenomas and its potential role as a molecular therapeutic target in pituitary adenomas will be summarized.

Entities:  

Keywords:  Biomarker; Pituitary adenomas; Signal transducer and activator of transcription 3 (STAT3)

Mesh:

Substances:

Year:  2021        PMID: 34248112     DOI: 10.1507/endocrj.EJ21-0106

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  1 in total

1.  The kinome, cyclins and cyclin-dependent kinases of pituitary adenomas, a look into the gene expression profile among tumors from different lineages.

Authors:  Keiko Taniguchi-Ponciano; Lesly A Portocarrero-Ortiz; Gerardo Guinto; Sergio Moreno-Jimenez; Erick Gomez-Apo; Laura Chavez-Macias; Eduardo Peña-Martínez; Gloria Silva-Román; Sandra Vela-Patiño; Jesús Ordoñez-García; Sergio Andonegui-Elguera; Aldo Ferreira-Hermosillo; Claudia Ramirez-Renteria; Etual Espinosa-Cardenas; Ernesto Sosa; Ana Laura Espinosa-de-Los-Monteros; Latife Salame-Khouri; Carolina Perez; Blas Lopez-Felix; Guadalupe Vargas-Ortega; Baldomero Gonzalez-Virla; Marcos Lisbona-Buzali; Daniel Marrero-Rodríguez; Moisés Mercado
Journal:  BMC Med Genomics       Date:  2022-03-08       Impact factor: 3.063

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.